Spots Global Cancer Trial Database for rash
Every month we try and update this database with for rash cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Systemic and Topical Treatments for Rash Secondary to Erlotinib in Lung Cancer | NCT00473083 | Rash | Minocycline Clindamycin 2% ... Erlotinib Topical clindam... | 18 Years - | British Columbia Cancer Agency | |
| FOLFIRI in Combination With Cetuximab in the First-line Treatment of Metastatic Colorectal Cancer Including a Regular Dermal Prophylaxis to Prevent Acneiforme Follicular Exanthema | NCT01315990 | Colorectal Canc... | FOLFIRI + Cetux... | 18 Years - | Johannes Gutenberg University Mainz | |
| Subcutaneous Amifostine Safety Study | NCT00158041 | Head and Neck C... Lung Cancer Lymphoma | Amifostine admi... | 18 Years - | Mt. Sinai Medical Center, Miami | |
| Study of Acitretin to Treat Skin Rash Caused by Erlotinib (a Chemotherapy Drug) | NCT01299220 | Skin Rash | Acitretin | 18 Years - | University of Pittsburgh | |
| Effect of Sorafenib or Regorafenib on P63 Expression and Keratinocyte Differentiation in Human Skin | NCT01466504 | Renal Cell Carc... Hepatocellular ... Colorectal Carc... | skin punch biop... | 18 Years - | Dartmouth-Hitchcock Medical Center | |
| Effect of Sorafenib or Regorafenib on P63 Expression and Keratinocyte Differentiation in Human Skin | NCT01466504 | Renal Cell Carc... Hepatocellular ... Colorectal Carc... | skin punch biop... | 18 Years - | Dartmouth-Hitchcock Medical Center | |
| A Study to Prevent Rash in People Starting Alpelisib for the Treatment of Breast Cancer | NCT05966584 | Breast Cancer | Benralizumab fulvestrant or ... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Safety, Tolerability and Efficacy Study of Doxycycline Foam for the Prevention of EGFRI Skin Toxicity in Cancer Patients | NCT02239731 | Rash Due to Epi... | FDX104 (4% Doxy... | 18 Years - | Vyne Therapeutics Inc. | |
| Erlotinib Pharmacokinetics During Doxycycline Treatment for Erlotinib-induced Rash | NCT00803842 | Non Small Cell ... | doxycycline | 18 Years - | Northwestern University | |
| FOLFIRI in Combination With Cetuximab in the First-line Treatment of Metastatic Colorectal Cancer Including a Regular Dermal Prophylaxis to Prevent Acneiforme Follicular Exanthema | NCT01315990 | Colorectal Canc... | FOLFIRI + Cetux... | 18 Years - | Johannes Gutenberg University Mainz | |
| Effect of Sorafenib or Regorafenib on P63 Expression and Keratinocyte Differentiation in Human Skin | NCT01466504 | Renal Cell Carc... Hepatocellular ... Colorectal Carc... | skin punch biop... | 18 Years - | Dartmouth-Hitchcock Medical Center | |
| Effect of Sorafenib or Regorafenib on P63 Expression and Keratinocyte Differentiation in Human Skin | NCT01466504 | Renal Cell Carc... Hepatocellular ... Colorectal Carc... | skin punch biop... | 18 Years - | Dartmouth-Hitchcock Medical Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
